Contributing to the promise of Surgical Oncology
17 March 2017
Researchers and clinicians from Melanoma Institute Australia (MIA) are meeting with more than 1,700 colleagues from around the world today at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium in Seattle, USA. The theme of the meeting is “discovering the promise of what’s possible” and invites attendees to learn about the exciting possibilities for improving oncologic outcomes for patients.
The conference provides surgical oncology leaders with an opportunity to share research and network to advance the field. Four of MIA’s current or former fellows are presenting their research to colleagues at the conference, in addition to several more in attendance.
MIA's 2016 Poche Surgical Fellow, Dr Kim Isaacs, is sharing her research at the conference. Most guidelines recommend that melanoma patients have a complete lymph node dissection after they have had a positive sentinel lymph node identified; however, this doesn’t always happen. Dr Isaacs’s research investigated the factors that influence a melanoma patient’s choice to have a complete lymph node dissection or not. This research will help determine why some patients are not going ahead with this potentially life-saving surgery.
Research fellow, Trine Schoenfeldt, from Denmark is presenting her MIA research that is looking at the ideal surgical management for patients who have melanoma metastases in the sentinel nodes located near their armpit (specifically the triangular intermuscular space). How to manage patients with these metastases is considered controversial for surgeons, so having scientific evidence about the best course of treatment will ensure the best care for patients.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
A round of applause for a well deserved win.
A message from our CEO, Carole Renouf
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.
Melanoma Institute Australia's annual fundraising initiative is all systems go!
The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.